Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 1:Magnitude and Moderators of the Problem

Andrade, Chittaranjan

doi:10.4088/jcp.16f10997

Cited by 18 publications

(14 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Amisulpride is effective for the improvement of both positive and negative symptoms of schizophrenia and possesses a safety profile that compares favorably with other second-generation antipsychotics 14–16. In particular, amisulpride is associated with less weight gain, which is an important consideration given the reported contribution of weight gain and metabolic syndrome to mortality and morbidity in patients with schizophrenia 17–19. In addition, amisulpride has a low risk of drug–drug interactions with other antipsychotics, which makes switching to this treatment relatively straightforward 12,20,21.…”

Section: Introductionmentioning

confidence: 99%

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study

Liang

2017

NDT

View full text Add to dashboard Cite

IntroductionSecond-generation antipsychotics show significant interpatient variability in treatment response and side-effect profiles, and the majority of patients with schizophrenia require multiple treatment changes. This subgroup analysis of the ESCAPE study evaluated the efficacy and safety of amisulpride in Chinese patients with schizophrenia who switched from risperidone or olanzapine.MethodsESCAPE was a prospective, open-label, multicenter, single-arm Phase IV study in which Chinese patients with an ICD-10 diagnosis of schizophrenia received amisulpride for 8 weeks. This analysis included 109 patients who switched to amisulpride from risperidone (n=68) or olanzapine (n=41) and 59 treatment-naïve patients for reference. The primary effectiveness outcome was a ≥50% decrease in Positive and Negative Syndrome Scale (PANSS) Total score from Baseline to Week 8. The study was registered at ClinicalTrials.gov (NCT01795183).ResultsOf the patients who switched from risperidone and olanzapine, 77.9% and 56.1% achieved ≥50% reduction in PANSS Total score from Baseline to Week 8 and 57.4% and 46.3% achieved ≥20% reduction in PANSS score from Baseline to Week 2, respectively; these end points were achieved by 66.1% and 61.0% of treatment-naïve patients, respectively. No unexpected adverse events (AEs) were reported. Of the most common AEs, extrapyramidal side effects occurred in 32.4% and 14.6%, blood prolactin increase in 32.4% and 39.0%, and ≥7% increase in body weight in 4.4% and 12% of patients switching from risperidone and olanzapine, respectively.ConclusionThe results of this subgroup analysis suggest that switching to amisulpride from risperidone and olanzapine is effective and generally well tolerated in Chinese patients with schizophrenia.

show abstract

Section: Introductionmentioning

confidence: 99%

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study

Liang

2017

NDT

View full text Add to dashboard Cite

show abstract

“…Studies showed that patients with schizophrenia have higher risk of having medical morbidity and mortality risks than general population,8) and weight gain, in association with metabolic syndromes, has continuously reported to be an important contributing factor to this higher morbidity and mortality of schizophrenia 9). Recent studies repeatedly showed concerns metabolic SE profiles of AAPs,10–13) henceby metabolic profile including weight gain became one of the most important reasons for switching AAP from one to another 14–16)…”

Section: Introductionmentioning

confidence: 99%

Amisulpride Switching in Schizophrenic Patients Who Showed Suboptimal Effect and/or Tolerability to Current Antipsychotics in a Naturalistic Setting: An Explorative Study

Kim

Wang

Kwak

et al. 2016

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

ObjectiveDespite numerous atypical antipsychotics (AAP) available, many patients with schizophrenia still experience lack of efficacy and persistent side-effects. Switching from one AAP to another with a different side-effect profile has become a common clinical strategy. We aimed to investigate effect of switching to amisulpride in patients who showed suboptimal effect and/or tolerability to current antipsychotics treatment.MethodsThis was a 6-week, prospective, multicenter, open-label, flexible-dose study in patients with schizophrenia. Switching to amisulpride was achieved using cross-titration within 7 days (day 1: 300 mg on day 1 then flexibly dosed 400–800 mg/day). The primary end-point measure was proportion of patients achieving improvement in clinical benefit at week 6 based on Clinical Global Impressions-Clinical Benefit (CGI-CB). Secondary endpoints included change in scores in CGI-CB, CGI-Severity (CGI-S), Subjective Satisfaction Scores (SSS), Brief Psychiatric Rating Scale (BPRS), and Simpson and Angus Rating Scale.ResultsAmong 37 patients switched to amisulpride, 76% completed study and 56.8% had clinical benefit measure by CGI-CB. CGI-CB and CGI-S scores showed significant improvement at week 6 compared to baseline (mean changes of CGI-CB and CGI-S scores: −1.7+1.0, p<0.0001 and −0.6±0.0, p=0.001, respectively). SSS scores also improved significantly (mean change: 2.1±2.6, p<0.0001). Mean weight of patients significantly lowered compared to baseline (mean change: −1.2±2.0, p<0.0001).ConclusionPatients with schizophrenia who showed suboptimal efficacy or tolerability with their current antipsychotics and thereby switched to amisulpride resulted in clinical benefit in terms of both improved efficacy and tolerability. The small sample size limits generalizability of the study results.

show abstract

“…These risk factors are evident early during the course of the illness and increase in prevalence after antipsychotic exposure. 1 Behavioral interventions, such as dietary guidance, exercise training, and combined diet and exercise (with psychoeducation and other behavioral elements included in the package) have not been shown to consistently improve cardiovascular health indices in patients with schizophrenia and other major mental illnesses 2 ; furthermore, there are challenges to the implementation of behavioral interventions in such patients. 3 The present article, the third in a series, examines whether pharmacologic interventions can mitigate the cardiometabolic risks.…”

Section: Introductionmentioning

confidence: 99%

Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 1:Magnitude and Moderators of the Problem

Cited by 18 publications

References 32 publications

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study

Amisulpride Switching in Schizophrenic Patients Who Showed Suboptimal Effect and/or Tolerability to Current Antipsychotics in a Naturalistic Setting: An Explorative Study

Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions

Contact Info

Product

Resources

About